Variables

Pre-treatment NLR

P value

<2.57 (n= 316)

≥2.57 (n = 72)

Age (years)

47.34 ± 10.03

46.85 ± 10.45

0.49

Menopausal status:

· Pre-menopausal

· Post-menopausal

154 (48.8%)

162 (51.2%)

37 (51.8%)

35 (48.2%)

0.36

Pathological type:

· IDC

· ILC

· Mixed

· DCIS

· Others

285 (90.1%)

15 (4.6%)

4 (1.3%)

1 (0.3%)

11(3.6%)

65 (90.6%)

3 (4.7%)

0

1 (1.2%)

3 (3.5%)

0.72

Histological grade:

· Grade I

· Grade II

· Grade III

4 (1.3%)

268 (88.4%)

31 (10.2%)

1 (1.2%)

76 (89.4%)

8 (9.5%)

0.06

Tumor stage:

· T1

· T2

· T3

· T4

· Tx

27 (8.3%)

181 (57.4%)

59 (18.8%)

30 (9.6%)

19 (5.9%)

6 (8.2%)

35 (49.4%)

14 (18.8%)

12 (17.6%)

5 (5.9%)

0.33

Nodal stage:

· N0

· N1

· N2

· N3

· Nx

95 (30%)

106 (33.7%)

53 (16.8%)

48 (15.2%)

14 (4.3%)

21 (29.4%)

21 (29.4%)

9 (12.9%)

16 (22.4%)

5 (5.9%)

0.49

Hormone receptor status:

· ER/PR positive

· ER positive and PR negative

· ER negative and PR positive

· ER/PR negative

163 (51.4%)

42 (13.2%)

9 (2.9%)

102 (32.2%)

38 (52.9%)

7 (10.6%)

2 (2.4%)

25 (34.1%)

0.09

HER-2 neu expression (by IHC):

· 0/+1

· +2

· +3

· Unknown

87 (27.4%)

18 (5.3%)

35 (11.6%)

176 (55.8%)

22 (30.6%)

4 (4.7%)

2 (3.5%)

44 (61.2%)

0.17

Triple negative:

22 (7%)

8 (10.6%)

0.21